DP Chemistry (last assessment 2024)

Syllabus sections »

Options » D: Medicinal chemistry » D.1 Pharmaceutical products and drug action

D.1 Pharmaceutical products and drug action

Description

[N/A]

Directly related questions

20N.3.sl.TZ0.12:
Consider the following antacids:

Show that antacid X is more effective, per tablet, than antacid Y.
20N.3.sl.TZ0.12:
Consider the following antacids:

Show that antacid X is more effective, per tablet, than antacid Y.
17N.3.sl.TZ0.18a:
Outline the difference between the therapeutic index in animal studies and the therapeutic index in humans.
17N.3.sl.TZ0.18a:
Outline the difference between the therapeutic index in animal studies and the therapeutic index in humans.
17N.3.sl.TZ0.a:
Outline the difference between the therapeutic index in animal studies and the therapeutic index in humans.
18M.3.sl.TZ1.13b.i:
State what is meant by the bioavailability of a drug.
18M.3.sl.TZ1.13b.i:
State what is meant by the bioavailability of a drug.
18M.3.sl.TZ1.b.i:
State what is meant by the bioavailability of a drug.
19M.3.hl.TZ1.22b:
Suggest a reason for using a phosphate salt of oseltamivir in oral tablets.
19M.3.hl.TZ1.22b:
Suggest a reason for using a phosphate salt of oseltamivir in oral tablets.
19M.3.hl.TZ1.b:
Suggest a reason for using a phosphate salt of oseltamivir in oral tablets.
19M.3.hl.TZ2.21a:
Distinguish between therapeutic window and therapeutic index in humans.

Therapeutic window:

Therapeutic index:
19M.3.hl.TZ2.21a:
Distinguish between therapeutic window and therapeutic index in humans.

Therapeutic window:

Therapeutic index:
19M.3.hl.TZ2.a:
Distinguish between therapeutic window and therapeutic index in humans.

Therapeutic window:

Therapeutic index:
19M.3.sl.TZ1.17a(ii):
Suggest a reason for using a phosphate salt of oseltamivir in oral tablets.
19M.3.sl.TZ1.17a(ii):
Suggest a reason for using a phosphate salt of oseltamivir in oral tablets.
19M.3.sl.TZ1.a(ii):
Suggest a reason for using a phosphate salt of oseltamivir in oral tablets.
17N.3.sl.TZ0.18b: State the method of drug administration that gives the maximum bioavailability.
17N.3.sl.TZ0.18b: State the method of drug administration that gives the maximum bioavailability.
17N.3.sl.TZ0.b: State the method of drug administration that gives the maximum bioavailability.
18M.3.sl.TZ2.15:
Drug testing is necessary to determine safe and effective doses.

Distinguish between the lethal dose (LD₅₀) and the toxic dose (TD₅₀).
18M.3.sl.TZ2.15:
Drug testing is necessary to determine safe and effective doses.

Distinguish between the lethal dose (LD₅₀) and the toxic dose (TD₅₀).
18N.3.sl.TZ0.12a: State the internal bond angles in the β-lactam ring and the expected bond angles for the same...
18N.3.sl.TZ0.12a: State the internal bond angles in the β-lactam ring and the expected bond angles for the same...
18N.3.sl.TZ0.a: State the internal bond angles in the β-lactam ring and the expected bond angles for the same...
18N.3.sl.TZ0.13c: Outline the meaning of the bioavailability of a drug.
18N.3.sl.TZ0.13c: Outline the meaning of the bioavailability of a drug.
18N.3.sl.TZ0.c: Outline the meaning of the bioavailability of a drug.
18N.3.hl.TZ0.17b: Outline the meaning of the bioavailability of a drug.
18N.3.hl.TZ0.17b: Outline the meaning of the bioavailability of a drug.
18N.3.hl.TZ0.b: Outline the meaning of the bioavailability of a drug.
19M.3.sl.TZ2.14a:
Distinguish between therapeutic window and therapeutic index in humans.

Therapeutic window:

Therapeutic index:
19M.3.sl.TZ2.14a:
Distinguish between therapeutic window and therapeutic index in humans.

Therapeutic window:

Therapeutic index:
19M.3.sl.TZ2.a:
Distinguish between therapeutic window and therapeutic index in humans.

Therapeutic window:

Therapeutic index:
19N.3.hl.TZ0.21b: Experimental research on both animals and humans contributes to the development...
19N.3.hl.TZ0.21b: Experimental research on both animals and humans contributes to the development...
19N.3.hl.TZ0.b: Experimental research on both animals and humans contributes to the development...
20N.3.sl.TZ0.11d:
Comment on the risk of overdose when taking aspirin as an analgesic, referring to the following values, for a person weighing $70 kg$ :

Minimum therapeutic dose $= 0.5 g$

Estimated minimum lethal dose $= 15 g$
20N.3.sl.TZ0.11d:
Comment on the risk of overdose when taking aspirin as an analgesic, referring to the following values, for a person weighing $70 kg$ :

Minimum therapeutic dose $= 0.5 g$

Estimated minimum lethal dose $= 15 g$
20N.3.sl.TZ0.d:
Comment on the risk of overdose when taking aspirin as an analgesic, referring to the following values, for a person weighing $70 kg$ :

Minimum therapeutic dose $= 0.5 g$

Estimated minimum lethal dose $= 15 g$
20N.3.hl.TZ0.15d:
Comment on the risk of overdose when taking aspirin as an analgesic, referring to the following values, for a person weighing $70 kg$ :

Minimum therapeutic dose $= 0.5 g$

Estimated minimum lethal dose $= 15 g$
20N.3.hl.TZ0.15d:
Comment on the risk of overdose when taking aspirin as an analgesic, referring to the following values, for a person weighing $70 kg$ :

Minimum therapeutic dose $= 0.5 g$

Estimated minimum lethal dose $= 15 g$
20N.3.hl.TZ0.d:
Comment on the risk of overdose when taking aspirin as an analgesic, referring to the following values, for a person weighing $70 kg$ :

Minimum therapeutic dose $= 0.5 g$

Estimated minimum lethal dose $= 15 g$

Sub sections and their related questions

None